The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.
Main Authors: | , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2013
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0100-879X2013000700607 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0100-879X20130007006072015-10-19The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trialsZhang,G.Zou,J.Liu,F.Bao,Z.Dong,F.Huang,Y.Yin,S. Moxifloxacin Helicobacter pylori Eradication rate Side effects Meta-analysis Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.46 n.7 20132013-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607en10.1590/1414-431X20132817 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Zhang,G. Zou,J. Liu,F. Bao,Z. Dong,F. Huang,Y. Yin,S. |
spellingShingle |
Zhang,G. Zou,J. Liu,F. Bao,Z. Dong,F. Huang,Y. Yin,S. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
author_facet |
Zhang,G. Zou,J. Liu,F. Bao,Z. Dong,F. Huang,Y. Yin,S. |
author_sort |
Zhang,G. |
title |
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
title_short |
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
title_full |
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
title_fullStr |
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
title_full_unstemmed |
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
title_sort |
efficacy of moxifloxacin-based triple therapy in treatment of helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials |
description |
Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection. |
publisher |
Associação Brasileira de Divulgação Científica |
publishDate |
2013 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607 |
work_keys_str_mv |
AT zhangg theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT zouj theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT liuf theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT baoz theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT dongf theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT huangy theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yins theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT zhangg efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT zouj efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT liuf efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT baoz efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT dongf efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT huangy efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yins efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials |
_version_ |
1756391426764046336 |